Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

76.99 -1.75 (-2.22%)
Streaming Delayed Price Updated: 10:03 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,205,740
Open 78.28
Bid (Size) 76.97 (1)
Ask (Size) 77.01 (2)
Prev. Close 78.74
Today's Range 76.03 - 78.85
52wk Range 75.93 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 4.21%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck & Co. Reports Better Than Expected Results For First-Quarter 2025
Merck's Q1 2025 results show a slight decrease in total sales but highlight growth in key segments. 
Via Talk Markets
Topics Stocks / Equities
Durable Goods Orders Jump 9.2% In March, But One Category Tells The Real Story
US durable goods orders surged in March, but with a mixed picture. Transportation equipment led the gain, while other sectors showed minimal growth or decline. 
Via Benzinga

Performance

YTD
-22.4%
-22.4%
1 Month
-16.6%
-16.6%
3 Month
-19.5%
-19.5%
6 Month
-27.6%
-27.6%
1 Year
-39.3%
-39.3%

More News

Read More
Merck Reports Strong Q1 Earnings But Downgrades Full-Year Guidance: Retail Sentiment Brightens
Via Stocktwits
Topics Government World Trade
Exposures Political Tariff
Merck’s (NYSE:MRK) Q1 Sales Beat Estimates
Via StockStory
Topics Artificial Intelligence Earnings Intellectual Property
Exposures Artificial Intelligence Financial Intellectual Property
Earnings Scheduled For April 24, 2025
Via Benzinga
Gardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit?
Via Investor's Business Daily
Topics Earnings Government Stocks
Exposures Financial Political US Equities
Merck Announces First-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Via Benzinga
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?
Via Benzinga
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
Via Investor's Business Daily
Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings
Via StockStory
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer
Via Benzinga
Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved
Via Stocktwits
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Why Merck, Black Hills, And Virtus Investment Partners Are Winners For Passive Income
Via Benzinga
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Via Benzinga
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Assessing Merck & Co: Insights From 9 Financial Analysts
Via Benzinga
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Price Over Earnings Overview: Merck & Co
Via Benzinga
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
Via Benzinga
Marjorie Taylor Greene Made Large Stock Purchases Ahead Of Trump's 90-Day Tariff Pause: Hakeem Jeffries Calls It 'Problematic'
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi, LLP
Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 76.99
When was Merck & Co last traded?
The last trade of Merck & Co was at 04/24/25 10:03 AM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 194.89B
How many shares of Merck & Co are outstanding?
Merck & Co has 195B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.